Exosome Therapeutics Market 2022 – Industry Growth by 2035 In recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse target indication, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. As a result, exosome therapeutics domain has been gaining traction recently. INTRODUCTION TO EXOSOMES Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA, based on the type of cell of their origin and its conditions. Exosomes convey a wide range of information to the target cells, depending on their source. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA. TYPES OF EXTRACELLULAR VESICLES Micro-vesicles have size of about 100 nm and are formed by direct outward budding of the plasma membrane. Their formation solely depends on the surrounding environment and this process requires the presence of cytoskeleton components, namely actin/ Exosomes have a diameter in the range between 30-150 nm and are formed by inward budding and get developed into the multivesicular bodies (MVBs). Owing to their long half-life, exosomes can target specific organs of the body, which makes them widely studied vesicles for immunological purposes. Apoptotic bodies have a diameter of about 5,000 nm and formed after the separation of plasma membrane from the skeleton. They can be easily distinguished from micro vesicles and exosomes because of their unscathed organelles as well as chromatin. EXOSOME BIOGENESIS, FORMATION, DEVELOPMENT AND SECRETION Exosomes are known to arise from the inward folding of multi-vesicular bodies (MVBs) in order to form the intraluminal vesicles (ILVs). These MVBs are then delivered to the trans-Golgi network (TGN) for the recovery of endosomes, which further move to lysosome for degeneration of the carried substances. The most essential component of exosome biogenesis is the formation of ESCRT. Formation and development of exosomes:  Sorting of internalized cargoes into early endosomes  Maturation into late endosomes or multivesicular bodies  Delivery of cargoes from trans-Golgi network and cytosol  Exosomes cargo in multivesicular bodies are transported to plasma membrane  Fusion with the plasma membrane  Secretion of exosomes ADVANTAGES AND FUTURE POTENTIAL OF EXOSOME THERAPEUTICS: Advantages:  High Compatibility: Exosomes are naturally occurring compounds that can withstand digestive enzymes.  Low Immunogenicity: Due to the innate properties of exosomes including their potential tissue of cell selectivity.  Targeted Drug Delivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity. Future Potential:  Several emerging players have undertaken initiatives to explore the potential of exosomes for diagnosis of various diseases.  Application of exosomes as biomarker or vector of various potential therapeutic molecules, represents a theragnostic approach.  Advanced exosome technologies are being developed to fully substructure the potential therapeutic applications of exosomes. For additional details, please visit https://www.rootsanalysis.com/blog/introduction-to-exosome-therapeutics/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities The application of digital twins in healthcare has the potential to revolutionize patient care, improve clinical outcomes, and reduce costs. Digital twins, or virtual replicas of physical objects and environments, are being used in many different industries, and healthcare is no exception. In healthcare, these can be used to provide better patient monitoring, improve remote care, and create personalized treatments. What is a Digital Twin? Digital twins are virtual representations of real-world objects. A digital twin is a piece of equipment, for example, may have the same functionality as the physical counterpart. Digital twins can be created using a wide range of data sources, such as sensors, models, and images. In the context of healthcare, these technologies can include the full representation of a patient’s medical history, symptoms, current treatment, and even biometric data, such as blood pressure and heart rate. Benefits Associated with The Use of Digital Twins Digital twins offer many benefits to the healthcare industry. In the following sections, we explore the top three benefits offered by digital twin technologies. • Real-Time Data Access – While physical objects can be monitored and controlled, the data is often delayed. A digital twin, on the other hand, can be almost immediately updated with data. This means that healthcare providers can see and respond to real-time changes / real world evidence and abnormalities. • Improved Remote Care – Remote care is when healthcare is provided to patients who are not physically in a healthcare facility. Remote care is growing in popularity, but it comes with several challenges, such as a lack of real-time data and an inability to supervise the patient. Digital twins can help with these challenges by providing real-time data and allowing healthcare providers to view the patient remotely (telemedicine support). Disadvantages Associated with The Use of Digital Twins For all the benefits of digital twins, there are still some challenges that need to be addressed. In the following sections, we explore the top three challenges. • Difficulty in Adoption – Digital twins have been in use since the early 2000s, but they have only recently started to be used in healthcare. This is largely due to the fact that digital twins have been primarily used in industrial settings and that the concept has been hard for healthcare providers to grasp. While many find the concept of a digital twin attractive, it has been challenging for healthcare providers to adopt the concept. • Possibility of False Information – When data is fed into a digital twin, it can be inaccurate or incomplete. This can lead to incorrect findings and incorrect treatment plans. However, there are some efforts underway to solve this problem. One approach is to make the data used to create the digital twin as accurate as possible. Another approach is to let the digital twin correct itself based on new data. Future Perspectives In the following sections, we explore three ways in which the use of digital twins in healthcare can be improved. • Better Adoption Rates – With better adoption rates, healthcare providers will be able to use digital twins to their full potential. With the help of vendors and organizations, such as the Industrial Internet Consortium, healthcare providers can be better informed about the advantages of digital twins. Despite their immense rise in popularity, digital twins still have some issues that need to be resolved. As such, there are some ways in which the use of digital twins in healthcare can be improved. For additional details, please visit https://www.rootsanalysis.com/blog/digital-twins-in-healthcare/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Investment Opportunities in Women’s Digital Health Digital health is a broad term that refers to the utilization of communication and information technologies to manage, track, and improve the overall healthcare delivery system. Owing to the potential of digital technology to optimize patient healthcare and the development of pharmaceuticals, the digital healthcare industry has witnessed significant rise in investments in the past decade, including in the women’s digital health space. It is worth noting that the digital health initiative is mainly focused on developing and providing a range of easy-to-use and innovative tools to patients, scientists / researchers, healthcare professionals, and other industry stakeholders for better health management. A significant increase in adoption of digital solutions has been witnessed in this field, especially after the outbreak of pandemic. Over the years, several initiatives have been undertaken by various industry stakeholders across the globe to promote digital health solutions and their applications. For instance, in 2019, the Preventive Healthcare tool was launched by Facebook to connect people to different health resources, enabling its users to set reminders for checkups, schedule tests and track their past activity. Women’s Digital Health Women’s digital health or FemTech is a broad industry that offers various products, services, diagnostic tools, wearable devices, software, applications and technologies in order to address the issues associated with women’s health, including menstrual, reproductive, sexual, maternity, and menopause disorders. Since it is primarily focused on women’s healthcare, it has been termed as Female Technology or FemTech. In the past few years, several investments have been made by various institutional investors in the companies associated with women’s digital health sector. For instance, in April 2022, USD 28.5 million was raised by Evernow in venture series A for re-defining the menopause treatment. Additionally, in February 2022, USD 15 million was raised by Ro in venture series E to expand its direct-to-patient healthcare model. Key Application Areas of FemTech Industry The FemTech industry provides an opportunity for better self-management, enabling and empowering women to be more in control of their own health and wellbeing. Future Perspectives Owing to the increased adoption rate of digital solutions and rise in the demand for telehealth services, the companies involved in the women’s digital health domain have witnessed a surge in the investment activity. Subsequently, capital investments worth more than USD 3 billion have been made in this domain, over the past few years. Nearly 90% of the capital invested in the companies has, so far, come in from venture capital funding; some companies have already gone public. Moreover, there is a high unmet need in certain areas, such as management of mental health, disease conditions, such as PCOS, endometriosis and disease which have high prevalence among women. In order to identify the gaps and unmet needs, it is important to develop customized and focused solutions, and establish policies that can help in increasing awareness about women’s health. Given the potential of digital health solutions, with the development of affordable and accessible digital technologies, the healthcare service industry is expected to witness noteworthy growth in the coming years. Furthermore, taking into consideration the ongoing efforts to develop solutions for existing unmet needs, we expect the women’s digital health market to present numerous lucrative investment opportunities in the future. For additional details, please visit https://www.rootsanalysis.com/blog/womens-digital-health/ You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Genotoxicity Testing: Unlocking the Future Safety Assessment Opportunities Genotoxicity testing refers to the evaluation of detrimental effects of chemical or physical agents on the genetic processes and related hereditary material of living cells. On the other hand, mutagenicity is the process of inducing irreversible and transmissible alterations in the genetic material of organisms either spontaneously or through mutagenic activity. Disruption of the integrity and function of DNA at the gene or chromosomal level can lead to heritable mutations, resulting in genetic disorders, birth abnormalities, or cancer. Potential targets for DNA damage include somatic cells (confined to the exposed generation), germinal cells (potentially inherited effects), and mitochondria (detrimental to the exposed individual and progeny via maternal inheritance). Detrimental Effects of Genotoxins and Mutagens Genotoxins are chemical substances or radiations which causes genotoxicity leading to DNA or chromosomal damage, further leading to mutations. In eukaryotic organisms, damage to genetic material of somatic cell can lead to malignancy (cancer) whereas genetic damage to germ cells can result in heritable mutations that induce birth defects. Mechanism of Genotoxicity / Mutagenicity The interaction of genotoxins / mutagens with the structure of DNA causes damage to the genetic material. These genotoxic / mutagenic substances interact with the DNA structure at a specific base sequence, inducing deletion, mis-segregation, or non-disjunction, resulting in damage and mutation. Techniques Used for Genotoxicity / Mutagenicity Testing Genotoxins can be classified based on their effects into the following types: • Carcinogens: These have the ability to cause cancer. Examples – Asbestos, Benzene, Vinyl chloride and Carbon tetrachloride • Mutagens: These can induce mutations in the genetic material of an organism. Examples – Chloroform, Ethylene oxide, and Lead • Teratogens: These agents cause birth defects, abnormalities, or developmental problems in the offspring. Examples – Carbon monoxide, Lead and Xylene GENE MUTATION Ames Test: It is used to evaluate an agent’s mutagenic potential by reversing mutations in the tester mutant bacteria (E. coli, Salmonella typhi), as well as its ability to synthesize an essential amino acid required for growth MLA / HPRT: It is used to evaluate an agent’s mutagenic potential by reversing mutations in the tester mutant bacteria (E. coli, Salmonella typhi), as well as its ability to synthesize an essential amino acid required for growth Mutation Assay: Transgenic rodent somatic and germ cell gene mutation assay specifies an in vivo assay that perceives gene mutation causing agents. DNA DAMAGES Comet Assay: The comet assay, also known as single cell gel electrophoresis (SCGE), is an efficient technique for identifying DNA strand breaks in a cell. It is used in molecular epidemiology, genotoxicity testing, and basic studies on DNA damage and repair. CHROMOSOMAL DAMAGES Chromosomal Aberration Test: The comet assay, also known as single cell gel electrophoresis (SCGE), is an efficient technique for identifying DNA strand breaks in a cell. Micronucleus Test: The micronucleus identifies chemicals (liquid or solid) that lead to cytogenetic damage, resulting in the formation of micronuclei containing complete or lagging chromosomal segments. Applications of Genotoxicity / Mutagenicity Genotoxicity testing and mutagenicity testing can be employed in a wide range of industries. It detects the potential long-term effects of the compounds which are marketed without knowing their ability to affect human and environmental health. Recent Development and Future Perspectives Recent advancements in informatics and instrumentation technologies have facilitated the necessity to evaluate mutations and chromosomal damage caused by various chemicals. For additional details, please visit https://www.rootsanalysis.com/blog/genotoxicity-mutagenicity-testing/ You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Adeno-Associated Viral Vectors: Unlocking the Future Opportunities Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors-based drugs, LUXTURNA® and ZOLGENSMA®. In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors. In fact, a number of these companies also offer advanced technology platforms, enabling the processing of AAV vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective. 155+ Clinical Trials have been / are being conducted The stakeholders have invested extensively in conducting clinical trials for evaluating the efficacy of the therapeutic candidates in the treatment of a variety of indications. ~4,300 Patent Filed / Granted in the Domain Examples of leading industry stakeholders, in terms of most patent applications filed include Genzyme, Voyager Therapeutics, REGENXBIO, Baxalta and Spark Therapeutics. 200+ Partnerships and Collaborations signed in the Domain The growing partnerships and collaborations signed between different stakeholders is indicative of the significant demand of vectors and related therapies from the past few years. As projected by Roots Analysis, oncological disorders therapeutic area will have majority share in the adeno-associated viral vector market. As projected by Roots Analysis, the overall market of AAV vector manufacturers market is expected to expand in the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/adeno-associated-viral-vector/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Modular Construction – Retrofitting Conventional Buildings Shifting construction away from traditional sites and into factories could dramatically change the way we build. Will off-site builds bolster construction this time around? Over the years, construction has straggled behind other sectors in terms of efficiency. Off-site builds or modular construction is a powerful way to reform construction business saving more time, labor, cost and productivity mutually benefitting the manufacturer as well as the customer. What is Modular Construction? Modular Construction is a process in which different components known as Modules are constructed in a controlled factory setting and later assembled on the desired site as per the requirement of the user. In general, 60% to 90% of the work is completed offsite while the rest on the location where the facility is needed. The factory-made, standard modules are accustomed with walls, doors, ceilings, frames, and windows. Additionally, the modules can be integrated with more specific components, such as air handling units, fan filter units, air showers along with the lighting and plumbing facility intended for pharmaceutical use. It is worth mentioning, majority of the modular facilities built are GMP certified ensuring required quality standards have been met while construction. Types of Modular Construction Modular Construction can be broadly categorized into two categories, namely permanent and relocatable. Permanent modular builds mean the facilities are constructed to be used at the same location wherein it has been assembled. In other words, the building is similar to conventionally constructed infrastructure except the fact it has been built off-site. Need for Modular Facilities Conventional construction has never shown to surpass 80% mark owing to factors including logistical delays, type of material used, method of construction adopted and shortage of manpower eventually hampering the productivity. Whereas prefabricated approaches have reported to increase productivity by more than 100%. Modular construction acts as a sustainable method empowering today’s construction sector. The Modular Construction Process In the first phase, a description of the building that is to be constructed is created through discussion between the customer and modular building manufacturer followed by review of the engineering department to evaluate whether the proposed design meets all the applicable building codes. Then, granting of building permit is required in most jurisdictions for constructing new structures, or performing major renovations. Modular Construction in Pharmaceutical Industry The concept of modular construction has been used in other industries for a long time; however, over the past two to three decades, it has only gained significant attention within the pharmaceutical industry. Moreover, there is immense pressure on drug manufacturers to market novel drugs as soon as possible, before patent expiry. Increased pressure to expedite time to market, coupled with the need to decrease operating costs and increase manufacturing efficiencies, have amplified the value of smaller production facilities, which are more efficient and flexible. The modular construction market developments have made modular facilities more attractive to drug manufacturers today, as these facilities can quickly switch between multiple drugs, enabling formulation and packaging in multiple formats, such as solid, liquid, semi-solid and parenteral dosage forms. Roadblocks to Headway It is evident that shifting from conventional on-site construction to off-site modular construction can fundamentally avoid unforeseeable risks. However, on the other hand, construction of modular facilities may face certain challenges, in order to maintain the essentials of design and equipment of the facility. Some of the challenges with this approach may involve factors, such as logistics constraints, transportation, safety permits and communication barriers. For additional details, please visit https://www.rootsanalysis.com/blog/modular-construction-in-pharma-industry/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities LADD has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. These novel systems circumvent the limitations of conventional drug delivery system, such as multiple dosing frequency, fluctuating plasma levels, high toxicity levels and poor patient compliance. Principles and Strategies associated with Long-Acting Drug Delivery Lately, many technologies are being explored to develop long-acting drug in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The LADD technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. What are the Benefits of Outsourcing to Contract Service Providers (CDMOs / CDOs / CMOs)? One of the critical factors associated with the development of long-acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome. Bottom Line Keeping every trend in mind, Roots Analysis has provided complete information on market trends in long-acting drug delivery domain, which has some of the very recent and precise activities listed for the clients to help them make better decisions in its report titled, Long-Acting Drug Delivery Technologies and Services Market, 2023-2035. To find answers to key decision-making question and to know further about the market forecast analysis, highlighting the likely growth of the long-acting drug delivery technologies and services market, for the time period 2023-2035. For additional details, please visit https://www.rootsanalysis.com/blog/long-acting-drug-delivery-technologies/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Digital Therapies: The “Digital Pills” of current generation As per United Nation’s report, the current global population stands at around 8 billion and expected to reach 9 billion by the end of 2030. This increase in population is accompanied with a rise in the incidence of several chronic disease indications. In fact, as per a report published by National Association of Chronic Disease Director, by 2030 this increase of the chronic condition would cost the US economy about USD 2 trillion. Furthermore, the lack of medical awareness and vulnerability in the medical infrastructure is believed to make the things more complicated in the coming future. Therefore, in order to cater this need, a number of stakeholders have come up with the innovative solution of digitizing the healthcare industry with next generation tools, such as artificial intelligence, digital therapies, telemedicine, electronic health records and others. It is worth noting that these next generation techniques have demonstrated significant potential to improve the quality of lives of individuals suffering from chronic conditions. What is Digital Therapeutic? Digital Therapeutics is one of the many new initiatives undertaken by the stakeholders to cater the growing need. As per Digital Therapeutics Alliance, digital therapeutics is a software-based intervention to patients to treat, manage or prevent a disease or disorder. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes. Moreover, in order to be at par with the conventional medicines, several organizations have taken the initiative of validating their product in clinical trials for its safety and efficacy. In fact, the term “digital pills” has been coined due to its ability to compete against the conventional medicines/drugs. Furthermore, several organizations have undertaken key diverse initiatives in the field of digital therapies to support its growth as a new frontier in the healthcare sector. For instance, several organizations are focused on the development of prescription digital therapeutic solutions, wherein the product is prescribed by healthcare professionals or clinicians after confirmation of the eligibility of patients for using such solutions. In addition, to make digital therapeutics more engaging, these are currently being offered in a combination of software applications and others such as gaming solution, personal coach, and AI support. It is worth mentioning that the ease of use, personalized experience, accessibility, and convenience coupled with the COVID-19 pandemic, has popularized the digital therapeutics among the general population. In fact, countries, such as United States, Germany, UK, and others now have come up with their own laws to regulate the digital therapeutics among its population. For instance, in United States, the USFDA has implemented “Breakthrough Device Designation Program” for regularizing digital therapies as a medical intervention / solution for various indication. Likewise, UK have NHS based digital therapeutics database, wherein clinicians can refer for prescribing products and Germany has “Digital Health Act-2019”, for regularization of digital therapeutics. Bottom-Line Amidst growing competition, the availability of cutting-edge tools and technologies have emerged as a differentiating factor. This has caused many big pharma companies to actively expand their service portfolios, either through strategic acquisitions or entering into alliances with other digital therapeutic developers. Recent examples include AstraZeneca’s collaboration with digital therapeutics developer my health, wherein both the companies integrated their proprietary products for better outcome. You can also check out our report on digital therapies by visiting ‘digital health market ‘section. For additional details, please visit https://www.rootsanalysis.com/blog/digital-therapies-the-digital-pills/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Medical Device Coatings and Modification Technologies Over the past 50 years, the medical device industry has seen several notable developments. In fact, according to the World Health Organization (WHO), presently, around two million medical devices are available across the globe. Further, since 2020, the Food and Drug Administration (FDA) has approved 125 medical devices. The growing demand for complex medical devices, including implants, surgical equipment, catheters, and other invasive devices, has prompted the medical device developers to innovate and introduce biocompatible, high-performance medical device coatings that can meet the operational, clinical, and engineering requirements for these devices. Need for medical device coatings and Surface Modification Technologies The process of producing effective, functional as well as affordable, medical devices, when combined with the hygienic and biocompatibility requirements, develops unique quality challenges. In order to meet such challenges, the surface of biomaterial and biomedical devices is frequently coated, and tailored to alter the physiochemical properties, and the functionality of the surface, depending on the intended application. Types of Medical Device Coatings Biomedical devices have traditionally been made of different metals. More recently, different coating materials have been used to increase the biocompatibility of the medical equipment. Other desirable attributes provided by the medical device coating include reactivity to different stimuli, drug delivery / eluting capabilities, and anti-fouling traits. Further, medical coatings can be tailored to improve patient outcomes. They can also lengthen the device’s functional lives and increase their effectiveness. Some of the common types of coatings (on the basis of different applications) include lubricant coating, antimicrobial coatings and water-repellent polymers based coatings. Advantages of medical device coatings and Surface Modification Technologies The selection of a biomaterial for a medical device depends on several factors that can affect the present as well as future potential of the device. Notably, biocompatibility remains one of the most important factors. Each type of coating material / surface modification offers several advantages for the medical devices. Concluding Remarks With the increasing number of medical devices being approved across the globe each year, the demand for these technologies is increasing rapidly. In fact, there is a significant rise in the interest of such coatings and technologies amongst these developers. Hence, the medical device coatings and surface modification technologies domain can be expected to expand rapidly in the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/medical-device-coatings-and-modification-technologies/ You may also be interested in the following titles: 1. Flow Cytometry Service Market, 2022-2035 2. Gene Editing beyond CRISPR Market, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact Information Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

Demand for Outsourcing Biologics Fill Finish Services The increasing demand for biologics has led to an increasing need for production capacity, which is characterized by high quality standards. Although, it is a challenging field, outsourcing has emerged as a promising segment, especially for drug product manufacturing and aseptic fill / finish operations. Despite being one of the crucial steps of all the steps involved in the production of biologics, fill finish is heavily outsourced activities in the pharmaceutical industry. Currently, it is estimated that more than 50% of the overall operations are outsourced to service providers. Service providers offering these services are using vials for filling of biologics. Of these, over 70% of service providers operate at clinical and commercial scales of operation. Of the players offering these services for biologics are headquartered in Asia-Pacific. More than 35% of these players are located in China. Further, of these, more than 40% players are well established players. Expansions have been witnessed by the industry, since 2013 to cater to the increasing need of their clients; of these, 55% expansions are associated with the establishment of new facility or adding area to the existing facility. Of global biologic fill finish capacity available in the facilities established by services providers is for filling of vials. Further, majority of capacity is available with service providers headquartered in Asia-Pacific. As projected by Roots Analysis, antibodies will have the highest share in this market. This trend is likely to continue in the future. In addition, majority of the market is likely to be driven by the filling of vials and syringes. More than 35% of these service providers are headquartered in Europe. Over 20% of these players were established before 1960 and 45% of the players were established after 2000. With outsourcing being increasingly accepted as a viable / beneficial business model and the anticipated growth in the biologics market, the opportunity for fill finish biopharmaceuticals service providers is expected to grow at a steady pace over the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/demand-for-outsourcing-biologics-fill-finish/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com